PCSK9 inhibitors and dyslipidemia: The clinical evidence

QR Code

PCSK9 inhibitors and dyslipidemia: The clinical evidence

Elevated plasma LDL cholesterol (LDL-C) levels are associated with cardiovascular diseases and statin therapy was proven to decrease LDL-C and reduce cardiovascular death. However, in patients at high cardiovascular risk, achievement of optimal LDL-C levels is challenging, and therefore additional s...

Full description

Bibliographic Details
Main Author:	Norata, Giuseppe
Format:	Journal Article
Published:	2014
Online Access:	http://hdl.handle.net/20.500.11937/55905

Similar Items

Targeting PCSK9 for hypercholesterolemia
by: Norata, Giuseppe, et al.
Published: (2014)

PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
by: Norata, Giuseppe, et al.
Published: (2014)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?
by: Casula, M., et al.
Published: (2017)

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
by: Tibolla, G., et al.
Published: (2011)

Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
by: Baragetti, A., et al.
Published: (2018)

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
by: Baragetti, A., et al.
Published: (2017)

Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’
by: Watts, G., et al.
Published: (2018)

A systematic review of the evidence for pharmacist care of patients with dyslipidemia
by: Charrois, Theresa, et al.
Published: (2012)

Prevalence of arterial stiffness and dyslipidemia
by: Abdul Kareem, Azmad, et al.
Published: (2012)

Arterial stiffness and its association with dyslipidemia
by: Mohd Rus, Razman, et al.
Published: (2013)

In vivo and in vitro effects of phaleria macrocarpa (scheff.) boerl on low density lipoprotein and pcsk9 expression
by: Chong, Soo Ching
Published: (2011)

Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in vivo and in vitro.
by: Chong, Soo Ching, et al.
Published: (2011)

Physical activity, nutrition, and dyslipidemia in middle-aged women
by: Delavar, Mouloud Agajani, et al.
Published: (2011)

Association Of Single Nucleotide Polymorphisms (Snp) In Pcsk9 Gene With Lipid Analysis Among Iban And Bidayuh Ethnic Groups In Sarawak Population.
by: H. H., Hood, et al.
Published: (2015)

Intestinal postprandial chylomicrons: State of the union between liver, gut and dyslipidemia?
by: Proctor, S., et al.
Published: (2008)

Prediction Of Uncontrolled Dyslipidemia Of Cardiac Outpatients And The Adverse Effect Of Pharmaceutical Excipients
by: Abdulrazzaq, Hadeer Akram
Published: (2013)

Dyslipidemia control and adverse drug reactions of statins among patients at cardiac clinic of Penang Hospital, Malaysia[RS1-441].
by: Alrazzaq, Hadeer Akram Abdul
Published: (2009)

PCSK9 inhibitory activity of marine-derived compounds, aaptaminoids, and benzamide originated from Aaptos aaptos and Acanthaster planci as a potential treatment for atherosclerosis.
by: Habsah, Mohamad, et al.
Published: (2020)

Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression?
by: Mamo, John, et al.
Published: (2001)

Vascular complications in type 2 diabetes mellitus patients and their association with hypertension and dyslipidemia
by: Khalid, Mohd Khairul Ashraf
Published: (2018)

Type 2 diabetes mellitus and atherogenic dyslipidemia: Which statin is most effective in the primary prevention of cardiovascular events?
by: Figg, Gemma
Published: (2012)

Evaluation Of Combined Metformin-Lovastatin Therapy In The Treatment Of Diabetic Type 2 Patients With Dyslipidemia In Hospital Pulau Pinang
by: Ghaith, Nada Faisal Zaki
Published: (2010)

Statins and skeletal muscles toxicity: From clinical trials to everyday practice
by: Norata, Giuseppe, et al.
Published: (2014)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering
by: Norata, Giuseppe, et al.
Published: (2016)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

Design, synthesis, and optimisation of highly selective macrocyclic CDK9 inhibitors
by: Gao, Rui
Published: (2018)

Long pentraxin 3: Experimental and clinical relevance in cardiovascular diseases
by: Bonacina, F., et al.
Published: (2013)

Prevalence and risk factors for dyslipidemia and hypertension in diabetes mellitus among the paediatric population in Hospital Universiti Sains Malaysia (USM), Kelantan, Malaysia
by: Shawaludin, Mohamad Qazreen Ahmad
Published: (2023)

Purine isosters in design and development of novel xanthin oxidase inhibitors
by: Luna, Giuseppe
Published: (2022)

New therapeutic principles for familial hypercholesterolemia
by: Norata, Giuseppe
Published: (2014)

Trained immunity and cardiovascular disease: Is it time for translation to humans?
by: Norata, Giuseppe
Published: (2018)

Mechanism Of Action Of A Benzimidazole Sirtuin Inhibitor, Bzd9l1, In Colorectal Cancer
by: Tan, Yi Jer
Published: (2022)

CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II-transcribed genes
by: Laitem, Clélia, et al.
Published: (2015)

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor
by: Whittaker, Steven R., et al.
Published: (2018)

Matrix Metalloproteinase -9 and Tissue Inhibitors of Metalloproteinasr-1 and -2 as Potential Novel Biomakers in Gestational Hypertension
by: Ab Hamid, Jabrullah
Published: (2010)

Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development
by: Hua, Y., et al.
Published: (2017)

Evaluation Of Renal Safety Of Raas Inhibitor Therapy: A Clinical And Pharmacovigilant Study
by: Khaleel, Mohammad Ali Mohammad
Published: (2024)

How clinically relevant are treatment comparisons of topical calcineurin inhibitor trials for atopic eczema?
by: Wilkes, Sally R., et al.
Published: (2016)

Cannot write session to /tmp/vufind_sessions/sess_26qnb84e4cotf602pk826nprsn